Biopsy tissues of 52 @entity1 with @entity2828 of bone treated between 1983 and 1993 were examined immuno-histochemically to determine the significance of @entity876 protein in diagnosis and prognosis of @entity2828 . Mean age at diagnosis was 17 years (range 6-36) and minimum follow-up was 30 months. The @entity5 were located in the extremities and central bones in 35 and 17 @entity1 respectively. @entity3 were present in seven @entity1 at diagnosis. Treatment consisted of chemotherapy, surgery and/or radiotherapy in all the @entity1 . Overexpression of @entity876 protein was demonstrated in seven @entity1 (14%). There was no relationship between expression of @entity876 and site of @entity5 . @entity1 who overexpressed @entity876 protein appeared to have more @entity1442 at diagnosis and poorer response to chemotherapy than those without @entity876 overexpression. The 5-year relapse-free survival and overall survival in @entity1 without @entity3 at the time of diagnosis were 66% and 71%, respectively, in @entity876 protein-negative @entity1 compared with 20% relapse-free and overall survival in those with @entity876 protein overexpression (P= 0.01). The poorer prognosis in @entity876 protein-positive @entity1 was independent of site, local treatment or @entity39 of the @entity5 (P < 0.05). Over-expression of @entity876 protein is an independent poor prognostic factor in @entity2828 of bone.

Overexpression of @entity876 protein in primary XXXX of bone: relationship to @entity5 stage, response and prognosis.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2828 :: ('MESH:D012512', 'Disease') :: ["Ewing's sarcoma"] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced diseases'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'Metastases']
@entity2828 :: (MESH:D012512,Disease) :: ['Ewing's sarcoma']
